Tests an inhaler against a placebo inhaler in people with COPD and hyperinflation
Compares a combination inhaler with a placebo inhaler for heart and lung function in COPD.
Key facts
- Who runs it
- AstraZeneca
- Where
- Harefield, London, and Manchester, United KingdomSee the 3 sitesAlso in 1 other country, 4 sites
- Trial code
- Registry title
- A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 56 people, planned
- Started
- 24 Nov 2025
- Expected to end
- 31 May 2027
- Type of study
- Interventional, 2 groups
- Treatments tested
- Budesonide/Glycopyrronium/Formoterol Fumarate
- Placebo
- Metered dose inhaler
- Record updated
- 18 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 40 to 80 with COPD and lung hyperinflation who are current or former smokers and already use inhaled COPD maintenance treatment.
- Age
- 40 to 80 years
- Sex
- Women and men can join.
- Disease stage
- COPD confirmed by FEV1/FVC < 0.7, with pre-bronchodilator FEV1 < 80% at Visit 1, post-bronchodilator FEV1 of at least 30% and under 80% at Visit 2, mMRC of 1 or more, and hyperinflation (FRC > 135% of predicted normal).
- Earlier treatment
- Must be on mono-, dual-, or triple-inhaled maintenance COPD treatment.
- Biomarker or test result
- Blood eosinophil count < 300 cells/mm³ at Visit 1, with no eosinophil count > 300 cells/mm³ in the past 12 months.
Main reasons for not taking part
- Current asthma, asthma-COPD overlap, or another chronic lung disease besides COPD
- COPD flare needing hospital stay, or 2 or more needing systemic corticosteroids
- Past heart attack or acute coronary syndrome
- Serious heart rhythm problem, or a pacemaker or similar implanted heart device
- Lung infection within 8 weeks before Visit 1, or lung surgery such as lobectomy or lung volume reduction
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Current or former smoker with a history of ≥ 10 pack-years of tobacco smoking
- A diagnosis of COPD confirmed by a post-bronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) < 0.7
- At Visit 1: A pre-bronchodilator FEV1 < 80%
- At Visit 1: Peripheral blood eosinophil count < 300 cells/cubic millimeter (mm³), with no recorded history of eosinophil count > 300 cells/mm³ in the past 12 months
- At Visit 1: Modified Medical Research Council (mMRC) ≥ 1
- At Visit 2: A pre-bronchodilator functional residual capacity (FRC) of > 135% of predicted normal FRC
- At Visit 2: A post-bronchodilator FEV1 ≥ 30% and < 80% of the predicted normal value
- Participants must be on mono-, dual-, or triple-inhaled maintenance COPD treatment
- Female participants must either be not of childbearing potential or using a form of highly effective birth control
- All women of child bearing potential must have a negative pregnancy test at the Visit 1
Who cannot take part
- Participants who have had a respiratory tract infection within 8 weeks prior to Visit 1 and/or during the screening/run-in period
- Participants with lung lobectomy, lung volume reduction (during the study and within 3 months of Visit 1), or lung transplantation
- A current diagnosis of asthma, asthma-COPD overlap, or any other chronic respiratory disease other than COPD, such as alpha-1 antitrypsin deficiency, active tuberculosis, lung cancer, lung fibrosis, sarcoidosis, interstitial lung disease, and pulmonary hypertension
- History of a COPD exacerbation that required hospitalisation, or 2 or more COPD exacerbations that required systemic corticosteroids
- History of myocardial infarction or acute coronary syndrome
- History or current clinically significant atrial or ventricular arrhythmia to be confirmed by electrocardiogram (ECG)
- Participants with a cardiac implantable electronic device, including pacemaker, implantable cardioverter defibrillator, or cardiac resynchronization therapy
- Participants with ECG QTcF interval at Visit 1 > 460 milliseconds (ms) for males and > 480 ms for females
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 80 years old?
Where in United Kingdom
Also in 1 other country, 4 sites
- HarefieldHospital not named in the registryNo longer taking part
- LondonHospital not named in the registryTaking people
- ManchesterHospital not named in the registryTaking people
About the trial
What the trial wants to find out
The purpose of the study is to evaluate the effect of BGF MDI compared with placebo MDI on cardiac and lung function when administered in participants diagnosed with COPD and hyperinflation.
The 2 groups in the trial
- Sequence 1: BGF MDI and PlaceboTreatment being tested
Participants will receive BGF MDI in Period 1 followed by Placebo in Period 2.
Treatment: Budesonide/Glycopyrronium/Formoterol Fumarate, Placebo, and Metered dose inhaler
- Sequence 2: Placebo and BGF MDITreatment being tested
Participants will receive Placebo in Period 1 followed by BGF MDI in Period 2.
Treatment: Budesonide/Glycopyrronium/Formoterol Fumarate, Placebo, and Metered dose inhaler
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- A Randomised, Double-blind, Multi-centre, Placebo-controlled, Crossover Study to Assess the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler on Cardiac and Lung Function in Participants With Chronic Obstructive Pulmonary Disease and Hyperinflation
- Plain-language title
- Tests an inhaler against a placebo inhaler in people with COPD and hyperinflationGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07073950, who can take part
- Record updated
- 18 September 2026